Annual Plan | Liver Transplants | BCG Alternative, Cancer Information Highlights, 09/21/2022

National Cancer Institute sent this bulletin at 09/21/2022 11:10 AM EDT
National Cancer Institute

Having trouble viewing this email? View it as a Web page.

Bookmark and Share
Cancer Information Highlights
From the National Cancer Institute
Updating you about cancer causes, prevention, screening, treatment, coping, and more
 
New from NCI
NCI Annual Plan and Budget Proposal for Fiscal Year 2024
  Each year, NCI prepares a plan for advancing cancer research and proposes the budget required to fund a broad research portfolio, support the cancer research workforce, and sustain the infrastructure that makes progress against cancer possible.
Study Tackles Key Questions about Liver Transplants for People with Liver Cancer
drawing of liver with 3 small lesions   For some people with the most common type of liver cancer, a transplant is the only hope for a cure. A new study shows a high 10-year survival rate for people who got a liver transplant after their tumors were “downstaged” to become eligible for a transplant.
For Common Form of Bladder Cancer, Chemo Combo Effective Alternative to BCG

For the last 10 years, there has been a shortage of the standard treatment for high-risk non-muscle-invasive bladder cancer, a drug called BCG. Bladder cancer experts agree that a combination of gemcitabine and docetaxel is a good substitute for BCG.
Health Benefits from Black Tea

A study of tea drinkers in the United Kingdom showed that a higher intake of black tea was linked to a lower risk of death. Learn more about this NCI study.
Study Confirms that Immunotherapy Extends Life for Children with High-Risk Neuroblastoma
SET THIS ALT TEXT   Researchers have confirmed that the immunotherapy drug dinutuximab (Unituxin) can help children with high-risk neuroblastoma live longer. The finding is based on a trial of nearly 1,200 children with the disease.
Accelerated Approval for First Targeted Therapy for HER2-Mutant Lung Cancer

The Food and Drug Administration recently gave accelerated approval to trastuzumab deruxtecan (Enhertu) for adults with non-small cell lung cancer (NSCLC) that has a specific mutation in the HER2 gene. Around 3% of people with NSCLC have this kind of HER2 mutation.
 
Also of Interest
Childhood Cancers

When your child has cancer, it is natural to have many questions. Not all questions have answers, but the information and resources on this page are a good starting point.
COVID-19: What People with Cancer Should Know

The COVID-19 situation continues to change, and so does guidance from experts as they learn more. Read the latest on how to protect yourself from COVID-19, including new information from the Centers for Disease Control and Prevention about new COVID vaccines that target the Omicron variant.
Contact Us for Help

Information specialists at NCI’s Cancer Information Service (CIS), NCI's contact center, are available to help answer your cancer-related questions in English and Spanish. Reach us by phone, chat, or email.